MX9302033A - Acidos de hidroxialquilquinolina fluorados como antagonistas de leucotrieno. - Google Patents

Acidos de hidroxialquilquinolina fluorados como antagonistas de leucotrieno.

Info

Publication number
MX9302033A
MX9302033A MX9302033A MX9302033A MX9302033A MX 9302033 A MX9302033 A MX 9302033A MX 9302033 A MX9302033 A MX 9302033A MX 9302033 A MX9302033 A MX 9302033A MX 9302033 A MX9302033 A MX 9302033A
Authority
MX
Mexico
Prior art keywords
hydroxialkylquinoline
fluorated
acids
antagonists
leucotrene
Prior art date
Application number
MX9302033A
Other languages
English (en)
Inventor
Robert Zamboni
Daniel Guay
Marc Labelle
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of MX9302033A publication Critical patent/MX9302033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compuestos que tienen la fórmula (I): son antagonistas de leucotrieno e inhibidores de biosíntesis leucotrieno. Estos compuestos son útiles como agentes anti-asmáticos, anti-alérgicos, anti-inflamatorios, y citoprotectores. También son útiles para tratar angina, espasmo cerebral, nefritis glomerular, hepatitis,endotoxemia, uveitis, y rechazo de aloinjerto.
MX9302033A 1992-04-10 1993-04-07 Acidos de hidroxialquilquinolina fluorados como antagonistas de leucotrieno. MX9302033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/866,690 US5270324A (en) 1992-04-10 1992-04-10 Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
CN92105948A CN1080169A (zh) 1992-04-10 1992-06-16 含有水溶性药物的控释片

Publications (1)

Publication Number Publication Date
MX9302033A true MX9302033A (es) 1994-07-29

Family

ID=25742768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302033A MX9302033A (es) 1992-04-10 1993-04-07 Acidos de hidroxialquilquinolina fluorados como antagonistas de leucotrieno.

Country Status (21)

Country Link
US (1) US5270324A (es)
EP (1) EP0565185B1 (es)
JP (1) JP2504687B2 (es)
CN (2) CN1080169A (es)
AT (1) ATE168100T1 (es)
AU (1) AU653476B2 (es)
BG (1) BG62402B1 (es)
CA (1) CA2092896C (es)
CZ (1) CZ246394A3 (es)
DE (1) DE69319482T2 (es)
ES (1) ES2117691T3 (es)
FI (1) FI944734A0 (es)
HR (1) HRP930803A2 (es)
HU (1) HU218917B (es)
IL (1) IL105193A0 (es)
LV (1) LV12290B (es)
MX (1) MX9302033A (es)
NO (1) NO943792L (es)
SI (1) SI9300188A (es)
WO (1) WO1993021159A1 (es)
ZA (1) ZA932533B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
GB9216768D0 (en) * 1992-08-07 1992-09-23 Leo Pharm Prod Ltd Chemical compounds
ES2080656B1 (es) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
CA2130723C (en) * 1993-09-03 2006-01-31 Wilhelm Quittmann Process for preparing y-mercaptocarboxylic acid derivatives
DE4339724C1 (de) * 1993-11-22 1995-01-19 Siemens Ag Gasarmatur
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5427933A (en) * 1994-07-20 1995-06-27 Merck & Co., Inc. Reduction of phenylalkyl ketones to the corresponding (S)-hydroxy derivatives using mucor hiemalis IFO 5834
US5491077A (en) * 1994-07-20 1996-02-13 Merck & Co., Inc. Microbial method
GB9415997D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
US5545758A (en) * 1994-08-11 1996-08-13 Merck & Co., Inc. Process for the preparation of diisopinocampheylchloroborane
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5648448A (en) * 1995-06-06 1997-07-15 Hitachi Chemical Company, Ltd. Method of preparation of polyquinolines
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
IL125446A0 (en) * 1996-02-08 1999-03-12 Merck & Co Inc Pharmaceutical composition for the treatment of asthma allergy and inflammation
EP1041990B1 (en) * 1997-12-23 2006-06-28 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6696466B1 (en) 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
CA2371048C (en) 2002-02-06 2011-01-04 Delmar Chemicals Inc. Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
EP1507106B1 (de) * 2003-08-15 2007-07-18 ABB Turbo Systems AG Rotationsdichtung
US7553853B2 (en) * 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
MX2007001561A (es) * 2004-08-04 2007-04-16 Schering Corp Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas.
US20060110449A1 (en) 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
EP1948612A2 (en) * 2005-11-16 2008-07-30 Teva Pharmaceutical Industries Ltd Drying methods of montelukast sodium by azeotropic removal of the solvent
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EP1996552A1 (en) * 2006-03-17 2008-12-03 Synthon B.V. Montelukast amantadine salt
US20090326232A1 (en) * 2006-06-26 2009-12-31 Uttam Kumar Ray Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)
US7919505B2 (en) * 2006-07-11 2011-04-05 Schering Corporation Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
PL205444B1 (pl) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
EP2265586A4 (en) * 2008-03-17 2012-10-03 Reddys Lab Ltd Dr PREPARATION OF MONTELUKAST AND ITS SALTS
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
JP2012530140A (ja) 2009-06-16 2012-11-29 メルク・シャープ・アンド・ドーム・コーポレーション グルココルチコイド受容体アゴニストとしての新規［３，２−ｃ］ヘテロアリールステロイド、組成物およびこの使用
KR20140108627A (ko) * 2011-07-26 2014-09-12 썬 파마 어드밴스트 리서치 컴패니 리미티드 퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)
CN104069502B (zh) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
CN105085391B (zh) 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK282986A (da) * 1985-06-18 1987-02-24 Merck Frosst Canada Inc Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
US4962203A (en) * 1985-06-18 1990-10-09 Merck Frost Canada, Inc. 2-substituted quinolines useful as leukotriene antagonists
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
FR2617352B1 (fr) * 1987-06-26 1989-12-01 Eduvision Sa Procede de codage de donnees informatiques pour transmission aux normes video, videodisque mettant en oeuvre ledit procede et interface d'exploitation d'un tel videodisque
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
EP0318093A3 (en) * 1987-11-25 1990-12-05 Merck Frosst Canada Inc. Diarylquinoline diacids and their use as medicaments
DE3814504A1 (de) * 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3900261A1 (de) * 1988-05-31 1989-12-07 Bayer Ag Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
HU222344B1 (hu) * 1990-10-12 2003-06-28 Merck Frosst Canada & Co. Eljárás telítetlen hidroxi-alkil-kinolinsavak, és ezeket tartalmazó gyógyszerkészítmények előállítására
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists

Also Published As

Publication number Publication date
NO943792D0 (no) 1994-10-07
CN1080169A (zh) 1994-01-05
CA2092896A1 (en) 1993-10-11
EP0565185A1 (en) 1993-10-13
SI9300188A (sl) 1993-12-31
AU3686393A (en) 1993-10-14
LV12290B (en) 1999-11-20
FI944734A (fi) 1994-10-07
WO1993021159A1 (en) 1993-10-28
ZA932533B (en) 1993-11-04
HU9402905D0 (en) 1995-01-30
CN1083052A (zh) 1994-03-02
JP2504687B2 (ja) 1996-06-05
NO943792L (no) 1994-12-08
BG99085A (bg) 1995-06-30
AU653476B2 (en) 1994-09-29
JPH0625173A (ja) 1994-02-01
BG62402B1 (bg) 1999-10-29
LV12290A (lv) 1999-06-20
HRP930803A2 (en) 1994-12-31
CA2092896C (en) 2005-12-20
EP0565185B1 (en) 1998-07-08
DE69319482T2 (de) 1999-02-04
HUT70399A (en) 1995-10-30
ES2117691T3 (es) 1998-08-16
DE69319482D1 (de) 1998-08-13
HU218917B (hu) 2000-12-28
FI944734A0 (fi) 1994-10-07
CZ246394A3 (en) 1996-01-17
US5270324A (en) 1993-12-14
CN1043761C (zh) 1999-06-23
ATE168100T1 (de) 1998-07-15
IL105193A0 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
MX9302033A (es) Acidos de hidroxialquilquinolina fluorados como antagonistas de leucotrieno.
ES2114882T3 (es) Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.
FI920734A (fi) Ketosyror innehaollande kinoliner med leukotrienantagonisteffekt
FI953104A (fi) Diaryyli-5,6-kondensoidut heterosykliset hapot leukotrieeniantagonisteina
MX9101556A (es) Acidos hidroxialquilquinolina eter como antagonistas de leucotrieno.